Abstract
1. Stop injection/infusion immediately
2. Get extravasation kit
3. Put on (sterile) gloves
4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Original articles
Forssen EA, Tökes´ ZA: Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treat Rep 67: 481–484, 1983.
Madhavan S, Northfelt DW: Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 87: 1556–1557, 1995.
Balazsovits JA, Mayer LD, Bally MB, et al: Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23: 81–86, 1989.
Schmidmair M: personal communication, May 1999.
Lokich J: Doxil extravasation injury: a case report. Ann Oncol 10: 735–736, 1999.
Secondary literature
van Gemmern R: Gewebstoxizität und Paravasatbehandlung neuer Zytostatika. Krankenhauspharmazie 17: 471–473, 1996.
Dezube BJ: Safety assessment: Doxil® (doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi s sarcoma. Doxil Clinical Series 1: 1–7, 1997.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.
Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.
Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.
Gain M, Melzer S, Meyer-Jürshof A, et al: Pegyliertes liposomales Doxorubicin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 7: 49, 2003.
Gain M, Melzer S, Meyer-Jürshof A, et al: Liposomales Doxorubicin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 7: 38, 2003.
Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.
Summary of product characteristics Myocet® (Germany), Elan Pharma, October 2002.
Summary of product characteristics Caelyx® (Austria), SP Europe, Belgien, January 2003.
Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.
Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. Ann Oncol 15: 858–862, 2004.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Doxorubicin liposomal, Doxorubicin pegylated liposomal. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_30
Download citation
DOI: https://doi.org/10.1007/978-3-211-88893-3_30
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-88889-6
Online ISBN: 978-3-211-88893-3
eBook Packages: MedicineMedicine (R0)